Crossmark

Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome

Crossref DOI link: https://doi.org/10.1186/s40360-018-0202-9

Published Online: 2018-04-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Min

Xu, Min

Liu, Wei

Gao, Xin
Funding

Funding for this research was provided by:

Natural Science Foundation of Shandong Province (Grant No.ZR2015HQ028)

health technology development program in Shandong province (Grant No. 2016WS0724)
License Information

Text and Data Mining valid from 2018-04-03
More Information

Article History

Received: 3 October 2017

Accepted: 16 March 2018

First Online: 3 April 2018

Ethics approval and consent to participate

: The protocol of this study was approved by the Medical Ethics Committee of the 88th Hospital of PLA (Chinese People’s Liberation Army). The participants were informed about the details of the study, and signed their names to participate in this experiment. Participants under 18 years of age were signed by their parents on their behalf. They were totally voluntary and could withdraw from the study at any time. We can get information that could identify individual participants during or after data collection. The principle of voluntary and informed consent correspond to the Medical ethics standards.

: Not applicable

: The authors declare that they have no financial or non-financial competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.